Transgender Estradiol Affirming Therapy

• Status: Recruiting
• Trial end date: 2024-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this open label, pilot, randomized clinical trial is to evaluate the effectiveness, safety and tolerability of estrogen use in transgender female and the degree of testosterone suppression achieved in this population when placed on gender affirming pharmacological therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Hormones; Spironolactone

Criteria

Inclusion Criteria:

• Female transgender patients between the ages of 18 to 30 years of age who are seen at the Washington University Transgender Center. Patients must have met the eligibility and readiness criteria for gender-affirming hormone therapy.

Exclusion Criteria:

• GnRH agonist for the last 12 months

• History of liver disease

• Dyslipidemia requiring treatment

• Cigarette smoking

• Body mass index >30 kg/m2